-
A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
-
Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci
-
Cancer Res Treat. 2014;46(4):411-414. Published online July 18, 2014
-
DOI: https://doi.org/10.4143/crt.2013.093
-
-
Abstract
PDFPubReaderePub
- Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease.
In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, Sorafenib was administered for three months, and, finally, Positron Emission Tomography showed that the patient’s lesions had completely regressed.
-
Citations
Citations to this article as recorded by
- The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang Frontiers in Endocrinology.2020;[Epub] CrossRef - Primary Pulmonary Paraganglioma
Xin Huang, Qi-Lian Liang, Liang Jiang, Qiu-Long Liu, Wen-Ting Ou, Da-Heng Li, Hui-Jie Zhang, Gao-Le Yuan Medicine.2015; 94(31): e1271. CrossRef
-
11,755
View
-
97
Download
-
3
Web of Science
-
2
Crossref
|